Loading organizations...
Drug Hunter is a Happy Valley, Oregon-based company that provides a subscription-based platform compiling and distilling complex information on emerging drugs, patents, and technologies into a searchable reference database for drug discovery professionals. The organization currently serves over 200 research and development institutions, including major pharmaceutical companies, biotech firms, and academic centers, generating an estimated $20.3 million in annual revenue. Operating with a current workforce of 131 employees, the enterprise experienced a 51 percent growth in headcount over the past year and has secured $750,000 in total funding to date. The subscription service assists scientists in accelerating onboarding and applying modern drug discovery practices, guided by a leadership team that includes recognizable industry professionals such as Dennis Koester, Jennifer Hu, Lew Pennington, and Rory McAtee. Drug Hunter was officially founded in 2018 by Dennis Hu.
Drug Hunter has raised $6.0M across 1 funding round.
Drug Hunter has raised $6.0M in total across 1 funding round.
Drug Hunter has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Seed in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2025 | $6M Seed | — | FirstHand Alliance, Teamworthy Ventures | Announced |
Drug Hunter has raised $6.0M in total across 1 funding round.
Drug Hunter's investors include FirstHand Alliance, Teamworthy Ventures.
Drug Hunter is a subscription-based SaaS platform that aggregates and distills drug discovery insights from journals, patents, conferences, and other sources into a searchable knowledge base for pharmaceutical and biotech scientists.[1][2][4] It serves drug discovery teams at over 200 pharma and biotech companies, academic institutions, and innovators by solving the problem of information overload—saving users up to 10 hours monthly through curated case studies, competitive intelligence, and tools like structure search and patent analysis.[2][4] Formerly Rosalind Scientific, the company has raised $750K in unattributed funding, remains in early-stage operation since 2018, and demonstrates steady content momentum with frequent updates on emerging targets, modalities, and techniques like surface plasmon resonance (SPR).[1][5]
Founded in 2018 and based in Happy Valley, Oregon, Drug Hunter emerged from the need to streamline access to fragmented drug discovery knowledge, evolving from its prior incarnation as Rosalind Scientific.[1][2] The platform was built by scientists for scientists to address the daily challenge of sifting through thousands of disclosures across disparate sources, connecting dots in chemistry, biology, and pharmacology.[2][4] Early traction came from its unique distillation of real-world case studies and lessons, attracting endorsements from leaders at Amgen, Foghorn Therapeutics, Genesis Therapeutics, and large pharma DMPK directors, positioning it as a go-to resource amid growing demands for efficient competitive intelligence.[2]
Drug Hunter rides the wave of AI-accelerated drug discovery and targeted therapies, where exploding data from patents, trials, and modalities like protein degraders demands efficient synthesis amid a biotech funding resurgence.[2][5] Timing aligns with post-2023 market recovery, as pharma/biotech firms prioritize speed in hit-to-lead and competitive intel to counter high failure rates (over 90% in discovery).[4] Favorable forces include rising targeted protein degradation, non-peptide agonists, and tools like SPR for kinetics, which Drug Hunter spotlights, influencing the ecosystem by democratizing insights—empowering smaller biotechs against big pharma and fostering cross-company learning.[2][5]
Drug Hunter is poised to expand as a core intelligence hub, potentially integrating AI for predictive analytics on scaffolds or failure modes, amid trends like covalent drugs, degraders, and multi-specific modalities.[2][5] Its influence could grow through deeper partnerships, premium features for clinical-stage tracking, or ecosystem events like Flash Talks, solidifying its role in accelerating tomorrow's medicines. With modest funding and strong retention, scaling user base and content velocity will define its trajectory in a knowledge-starved field.
